Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan

References (27)

1. Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. PubMed CrossRef
2. Tang CT, Chua EC, Chew QH, et al. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia-Pac Psychiatry. 2020;12(4):e12393. PubMed CrossRef
3. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry suppl. 2009;52(SUPPL. 52):S63–S67. PubMed CrossRef
4. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992;53(12):426–433. PubMed
5. Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2-3):220–230. PubMed CrossRef
6. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260–267. PubMed CrossRef
7. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78(8):1136–1147. PubMed CrossRef
8. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94(2):118–124. PubMed CrossRef
9. Ballesteros J, González-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol. 2000;20(2):188–194. PubMed CrossRef
10. Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019;59:151–154. PubMed CrossRef
11. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3(0):03. PubMed CrossRef
12. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57(4):406–411. PubMed CrossRef
13. Morgenstern H, Glazer WM, Gibowski LD, et al. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population. J Chronic Dis. 1987;40(4):319–327. PubMed CrossRef
14. Kimura H, Kanahara N, Iyo M. Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behav Brain Res. 2021;403:113126. PubMed CrossRef
15. Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res. 2005;77(2-3):129–139. PubMed CrossRef
16. Gopal S, Xu H, Bossie C, et al. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. Int J Clin Pract. 2014;68(12):1514–1522. PubMed CrossRef
17. Kimura H, Kanahara N, Komatsu N, et al. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res. 2014;155(1-3):52–58. PubMed CrossRef
18. Pharmaceutical and Medical Device Regulatory Science Society of Japan. Medical Dictionary for Regulatory Activities/Japanese. PMRJ website. https://www.pmrj.jp/jmo/php/indexj.php.
19. Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–908. PubMed CrossRef
20. Niinomi I, Hosohata K, Oyama S, et al. Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database. Int J Toxicol. 2019;38(6):487–492. PubMed CrossRef
21. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–523. PubMed CrossRef
22. Misawa F, Okumura Y, Takeuchi Y, et al. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. Schizophr Res. 2021;231:42–46. PubMed CrossRef
23. Marder SR, Hubbard JW, Van Putten T, et al. Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology (Berl). 1989;98(4):433–439. PubMed CrossRef
24. Iyo M, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013;33(3):398–404. PubMed CrossRef
25. Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. PubMed CrossRef
26. Kang NR, Kim MD. Tardive dyskinesia: treatment with aripiprazole. Clin Psychopharmacol Neurosci. 2011;9(1):1–8. PubMed CrossRef
27. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486–487. PubMed CrossRef